---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-24-000059"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2024-07-10T23:59:59+00:00"
generated_at: "2026-05-31T22:24:08.502841+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Ligand ups revolving credit line to $125M from $75M

## Summary
- First amendment to Oct 2023 Credit Agreement executed July 8, 2024, increasing aggregate revolving commitments from $75M to $125M.
- Borrowing capacity expanded by $50M; no other material changes detailed in the filing.
- Credit facility includes subsidiaries as guarantors; Citibank remains administrative agent, swingline lender and L/C issuer.

## SEC filing metadata
- accession: 0000886163-24-000059
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2024-07-10T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 1.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616324000059/0000886163-24-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616324000059/lgnd-20240708.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-24-000059
- JSON: https://secwatch.observer/filing/0000886163-24-000059.json
- Plain text: https://secwatch.observer/filing/0000886163-24-000059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.